• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Sagimet Biosciences Inc.

    3/12/25 8:33:00 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SGMT alert in real time by email
    S-8 1 tm258742d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on March 12, 2025

    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

    SAGIMET BIOSCIENCES INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   20-5991472

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

    155 Bovet Road, Suite 303

    San Mateo, CA 94402

    (650) 561-8600

    (Address, including zip code and telephone number, including area code, of Registrant’s principal executive offices)

     

    Non-Qualified Stock Option Inducement Awards

    (Full title of the plans)

     

    David Happel

    President and Chief Executive Officer

    Sagimet Biosciences Inc.

    155 Bovet Road, Suite 303

    San Mateo, CA 94402

    (650) 561-8600

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

    Rachael M. Bushey
    Jennifer Porter

    Goodwin Procter LLP

    3025 John F Kennedy Blvd

    Philadelphia, PA 19104

    (445) 207-7805

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ¨   Accelerated filer   ¨
           
    Non-accelerated filer   x   Smaller reporting company   x
           
            Emerging growth company   x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration on Form S-8 registers shares of Series A common stock, $0.0001 par value per share (the “Common Stock”), of Sagimet Biosciences Inc. (the “Registrant”) issuable pursuant to equity awards granted by the Registrant to certain individuals in the amounts and on the dates detailed below (the “Inducement Awards”).

     

    ·Non-qualified stock options to purchase 643,548 shares of Common Stock granted to five employees on May 6, 2024; and

     

    ·Non-qualified stock options to purchase 252,435 shares of Common Stock granted to four employees on October 1, 2024.

     

    Each Inducement Award was approved by the Registrant’s Compensation Committee of the Board of Directors as an inducement material to the individual’s acceptance of employment with the Registrant in compliance with and in reliance on Nasdaq Listing Rule 5635(c)(4). The Inducement Awards were granted outside of the Registrant’s 2023 Stock Option and Incentive Plan (the “2023 Plan”) and its predecessor plans.

     

    Part I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The information specified in Part I of Form S-8 is omitted from this filing in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”) and the introductory note to Part I of the Form S-8 instructions. The documents containing the information specified in Part I will be delivered to the person to whom the Inducement Award has been granted as required by Rule 428(b)(1) under the Securities Act.

     

    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents of the Registrant, filed or to be filed with the Commission, are incorporated by reference in this Registration Statement as of their respective dates:

     

    (a)                 The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 12, 2025;

     

    (b)                the Registrant’s Current Reports on Form 8-K filed with the Commission on January 2, 2025, February 14, 2025, March 11, 2025, and March 12, 2025;

     

    (c)                 the description of the Registrant’s Common Stock contained in the Company’s Registration Statement on Form 8-A (File No. 001-41742) filed with the Commission on July 11, 2023, together with any amendment thereto filed with the Commission for the purpose of updating such description; and

     

    (d)                 all documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), prior to the filing of a post-effective amendment to this Registration Statement, which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement; provided, however, that documents, reports and definitive proxy or information statements, or portions thereof, which are furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement.

     

     

     

     

    Any statement contained herein or in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or amended, to constitute a part of this Registration Statement.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    Section 145 of the Delaware General Corporation Law (the “DGCL”) authorizes a corporation to indemnify its directors and officers against liabilities arising out of actions, suits and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as a director or officer to a corporation. The indemnity may cover expenses (including attorneys’ fees) judgments, fines and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action, suit or proceeding. Section 145 permits corporations to pay expenses (including attorneys’ fees) incurred by directors and officers in advance of the final disposition of such action, suit or proceeding. In addition, Section 145 provides that a corporation has the power to purchase and maintain insurance on behalf of its directors and officers against any liability asserted against them and incurred by them in their capacity as a director or officer, or arising out of their status as such, whether or not the corporation would have the power to indemnify the director or officer against such liability under Section 145.

     

    The registrant has adopted provisions in its Eleventh Amended and Restated Certificate of Incorporation (“Charter”) and second amended and restated Bylaws (“Bylaws”), each to be effective upon the closing of the registrant’s initial public offering, that limit or eliminate the personal liability of the registrant’s directors and officers to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended. Consequently, the registrant’s directors and officers will not be personally liable to the registrant or its stockholders for monetary damages or a breach of fiduciary duty in their capacities and directors and officers, except for liability:

     

      ● for any breach of a director or officer’s duty of loyalty to the registrant or its stockholders;
      ● for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law;
      ● for any transaction from which the director or officer derived an improper personal benefit;
      ● arising from any claim brought by or in the right of the registrant; and
      ● arising under Section 174 of the DGCL for directors.

     

    These limitations of liability do not alter director and officer liability under the federal securities laws and do not affect the availability of equitable remedies such as an injunction or rescission.

     

    In addition, the Bylaws provide that:

     

      ● the registrant will indemnify its directors, officers and, in the discretion of its board of directors, certain employees to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and
      ● the registrant will advance reasonable expenses, including attorneys’ fees, to its directors and, in the discretion of its board of directors, to officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of the registrant, subject to limited exceptions.

     

     

     

     

    The registrant has entered into indemnification agreements with each of its directors and officers. These agreements provide that the registrant will indemnify each of its directors, officers and, at times, their affiliates to the fullest extent permitted by the DGCL. The registrant will advance expenses, including attorneys’ fees (but excluding judgments, fines and settlement amounts), to each indemnified director, officer or affiliate in connection with any proceeding in which indemnification is available and the registrant will indemnify its directors and officers for any action or proceeding arising out of that person’s services as a director or officer brought on behalf of the registrant or in furtherance of the registrant’s rights. Additionally, certain of the registrant’s directors or officers may have certain rights to indemnification, advancement of expenses or insurance provided by their affiliates or other third parties, which indemnification relates to and might apply to the same proceedings arising out of such director’s or officer’s services as a director referenced herein. Nonetheless, the registrant has agreed in the indemnification agreements that its obligations to those same directors or officers are primary and any obligation of such affiliates or other third parties to advance expenses or to provide indemnification for the expenses or liabilities incurred by those directors are secondary.

     

    The registrant also maintains general liability insurance which covers certain liabilities of its directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act.

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8.Exhibits.

     

    The following documents are filed as exhibits to this Registration Statement:

     

    EXHIBIT INDEX

     

    Exhibit
    No.
      Description
         
    4.1   Eleventh Amended and Restated Certificate of Incorporation of Sagimet Biosciences Inc. (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-41742) filed on July 18, 2023).
         
    4.2   Second Amended and Restated Bylaws of Sagimet Biosciences Inc. (Incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, as amended (File No. 001-41742) filed on July 18, 2023).
         
    4.3   Form of Series A Common Stock Certificate of Sagimet Biosciences Inc. (Incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form S-1 (File No. 333-272901) filed on June 23, 2023).
         
    5.1*   Opinion of Goodwin Procter LLP.
         
    23.1*   Consent of Deloitte & Touche LLP, independent registered public accounting firm.
         
    23.2*   Consent of Goodwin Procter LLP (included in Exhibit 5.1).
         
    24.1*   Power of Attorney (included on signature page).
         
    99.1   Form of Inducement Option Award Agreement (Incorporated by reference to Exhibit 10.28 to the Registrant’s Annual Report on Form 10-K (File No. 001-41742) filed on March 12, 2025).
         
    107*   Filing fee table.  

     

    * Filed herewith.  

     

     

     

     

    Item 9. Undertakings.

     

    (a) The undersigned Registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i) to include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii) to reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and

     

    (iii) to include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

     

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the registration statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (h) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Mateo, State of California, on this 12th day of March, 2025.

     

      SAGIMET BIOSCIENCES INC.
         
      By: /s/ David Happel
        Name: David Happel
        Title: President, Chief Executive Officer and Director

     

    POWER OF ATTORNEY AND SIGNATURES

     

    KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of David Happel and Thierry Chauche, as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following person in the capacities and on the date indicated.

     

    NAME   TITLE   DATE
             
    /s/ David Happel   President, Chief Executive Officer and Director   March 12, 2025
    David Happel   Principal Executive Officer    
             
    /s/ Thierry Chauche   Chief Financial Officer   March 12, 2025
    Thierry Chauche   Principal Financial and Accounting Officer    
             
    /s/ George Kemble, Ph.D.   Executive Chairman of the Board   March 12, 2025
    George Kemble, Ph.D.        
             
    /s/ Elizabeth Grammer, Esq.   Director   March 12, 2025
    Elizabeth Grammer, Esq.        
             
    /s/ Merdad Parsey, M.D., Ph.D.   Director   March 12, 2025
    Merdad Parsey, M.D., Ph.D.        
             
    /s/ Jennifer Jarrett   Director   March 12, 2025
    Jennifer Jarrett        
             
    /s/ Beth Seidenberg, M.D.   Director   March 12, 2025
    Beth Seidenberg, M.D.        
             
    /s/ Anne Phillips, M.D.   Director   March 12, 2025
    Anne Phillips, M.D.        
             
    /s/ Paul Hoelscher   Director   March 12, 2025
    Paul Hoelscher        
             
    /s/ Tim Walbert   Director   March 12, 2025
    Tim Walbert        

     

     

     

    Get the next $SGMT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SGMT

    DatePrice TargetRatingAnalyst
    12/6/2024$30.00Outperform
    Oppenheimer
    11/12/2024$12.00Buy
    UBS
    6/28/2024$23.00 → $6.00Buy → Neutral
    Goldman
    5/2/2024$32.00Buy
    H.C. Wainwright
    3/25/2024$26.00Outperform
    Leerink Partners
    8/8/2023Outperform
    TD Cowen
    8/8/2023$67.00Overweight
    Piper Sandler
    8/8/2023$33.00Buy
    Goldman
    More analyst ratings

    $SGMT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Happel David bought $63,731 worth of Series A Common Stock (12,100 units at $5.27), increasing direct ownership by 2% to 639,200 units (SEC Form 4)

      4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

      3/28/24 4:08:37 PM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SGMT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Sagimet Biosciences with a new price target

      Oppenheimer initiated coverage of Sagimet Biosciences with a rating of Outperform and set a new price target of $30.00

      12/6/24 8:14:45 AM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on Sagimet Biosciences with a new price target

      UBS initiated coverage of Sagimet Biosciences with a rating of Buy and set a new price target of $12.00

      11/12/24 7:50:24 AM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sagimet Biosciences downgraded by Goldman with a new price target

      Goldman downgraded Sagimet Biosciences from Buy to Neutral and set a new price target of $6.00 from $23.00 previously

      6/28/24 8:12:54 AM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SGMT
    SEC Filings

    See more
    • Sagimet Biosciences Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - Sagimet Biosciences Inc. (0001400118) (Filer)

      6/10/25 5:17:10 PM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sagimet Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Sagimet Biosciences Inc. (0001400118) (Filer)

      6/4/25 6:03:02 AM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sagimet Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Sagimet Biosciences Inc. (0001400118) (Filer)

      5/8/25 6:05:59 AM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SGMT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sagimet Biosciences to Host Virtual KOL Event, "A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne" on June 16, 2025

      SAN MATEO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced it will host a virtual key opinion leader (KOL) event on Monday, June 16, 2025 at 2:00 PM ET. To register, click here. The event will feature key opinion leader (KOL) Neal Bhatia, MD (Director of Clinical Dermatology at Therapeutics Clinical Research in San Diego), who will join company management to review positive efficacy and tolerability results from a Phase 3 clinical trial evaluating denifanstat for the treatment of moderate to severe acne vulgar

      6/9/25 7:00:00 AM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis

      Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was well tolerated Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to severe acne Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, TVB-3567, that is planned to be developed for acne in the U.S. SAN MATEO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today reported denifanstat met all primary and secondary endpoints in a Phase 3 clinical trial for the treatment of

      6/4/25 5:00:00 AM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints

      Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated statistically significant and clinically meaningful improvement compared to placebo in all primary, key secondary, and secondary endpointsDenifanstat demonstrated a favorable safety and tolerability profileDenifanstat was 98% and 178% more effective than U.S. Food and Drug Administration (FDA)-approved sarecycline and doxycycline with regard to placebo-adjusted percent treatment success, respectively, 18.6% for denifanstat versus 9.4% for sarecycline, 18.6% versus 6.7% for doxycyclineDenifanstat was 60% more effective than FDA-approved clascoterone cream with regard to placebo-adjusted percent treatment

      6/3/25 7:15:00 PM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SGMT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Walbert Timothy P

      4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

      6/10/25 5:43:22 PM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Seidenberg Beth C

      4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

      6/10/25 5:42:20 PM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Phillips Anne M.

      4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

      6/10/25 5:41:17 PM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SGMT
    Leadership Updates

    Live Leadership Updates

    See more
    • Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

      SAN MATEO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointment of Thierry Chauche as Chief Financial Officer, effective today, May 6, 2024. "We are thrilled to welcome Thierry to our executive leadership team in the role of CFO. Thierry brings a proven track record in corporate finance in the biopharmaceutical sector, bringing expertise in corporate planning and strategy, investor relations, financing, and M&A," said Dave Happel, CEO of Sagimet. "Having an

      5/6/24 8:00:00 AM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

      SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi

      3/25/24 7:00:00 AM ET
      $IPSC
      $MIRM
      $RPHM
      $SGMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $SGMT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sagimet Biosciences Inc.

      SC 13G/A - Sagimet Biosciences Inc. (0001400118) (Subject)

      11/14/24 7:55:59 PM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Sagimet Biosciences Inc.

      SC 13G - Sagimet Biosciences Inc. (0001400118) (Subject)

      11/14/24 5:05:18 PM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sagimet Biosciences Inc.

      SC 13G/A - Sagimet Biosciences Inc. (0001400118) (Subject)

      11/14/24 4:31:38 PM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SGMT
    Financials

    Live finance-specific insights

    See more
    • Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

      Denifanstat Phase 2b FASCINATE-2 clinical trial 52-week data was presented in June at the European Association for the Study of the Liver (EASL) Congress Preparations are ongoing to initiate a Phase 3 clinical development program for denifanstat in patients with metabolic dysfunction-associated steatohepatitis (MASH) in the second half of 2024 Two biotechnology industry leaders, Anne Phillips and Jennifer Jarrett, joined the Board of Directors effective August 1, 2024 Anticipated cash runway through 2025 with cash, cash equivalents and marketable securities totaling $188.5 million as of June 30, 2024 SAN MATEO, Calif., Aug. 14, 202

      8/14/24 8:00:00 AM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat

      SAN MATEO, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced that it will host a conference call and webcast on Thursday, June 13, 2024, at 9.30 AM PT / 12:30 PM ET. The event will feature Rohit Loomba, M.D., M.H.Sc., Professor of Medicine, Chief, Division of Gastroenterology and Hepatology, and Director, MASLD Research Center, University of California San Diego, who was the Principal Investigator on the Phase 2b FASCINATE-2 clinical trial and serves as a scientific advi

      6/10/24 8:00:00 AM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care